[ad_1] Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx…
Tag: Diagnostic/Medical Research Services
Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2B
[ad_1] Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx…
Gene Editing Will Change Medicine—and Maybe Health Investing Too
[ad_1] It usually takes time for scientific discoveries in the lab to make their way to the market. The groundbreaking gene-editing technology known as Crispr, which acts like a molecular…
Sam Bankman-Fried to Take the Stand in Fraud Trial
[ad_1] Updated Oct. 25, 2023 11:32 am ET FTX founder Sam Bankman-Fried will testify at his criminal trial, his defense team said Wednesday, in what many legal observers see as…
Sam Bankman-Fried Took Risks at FTX. Will He Bet on His Own Testimony?
[ad_1] FTX founder Sam Bankman-Fried, known for his appetite for risky bets, is mulling perhaps his biggest gamble yet: testifying in his own defense. The onetime crypto star, on trial…
WSJ News Exclusive | Starboard Takes 5%-Plus Stake in Contract-Research Firm Fortrea
[ad_1] The activist investor plans to push for changes that could boost margins among other initiatives aimed at share-price appreciation. [ad_2] Source link
New Treatment for Bladder Cancer Offers This Biotech a Second Chance
[ad_1] UroGen hopes to have success with a new treatment after its first drug was a commercial flop. [ad_2] Source link
Pfizer’s Covid Boost Crashes to Earth
[ad_1] This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or…
Pfizer Misses Revenue Expectations, Bets on Drug Launches to Ease Shortfall
[ad_1] The company is rolling out 19 products or new uses within 18 months, CEO Albert Bourla said. [ad_2] Source link